How Global Mycoplasma Testing Market Players Should Strategize For 2022-2031

The global mycoplasma testing market size is expected to grow from $0.72 billion in 2021 to $0.81 billion in 2022 at a compound annual growth rate (CAGR) of 12.4%. The growth in the market is mainly due to a growing demand for these types of tests owing to an increase in spread of mycoplasma pneumonia. The mycoplasma testing market is expected to reach $1.29 billion in 2026 at a CAGR of 12.4%.

What is the Global Mycoplasma Testing Market?

The mycoplasma testing market consists of sales of mycoplasma testing services and related products by entities (organizations, sole traders, and partnerships) that provide mycoplasma testing to detect mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample.

Get a Sample of the global mycoplasma testing market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=4103&&type=smp

What drives the Global Mycoplasma Testing Market?

The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneumonia. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%.

Get the full global mycoplasma testing industry report here:

Global Mycoplasma Testing Market Segments
The global mycoplasma testing market is segmented:
By Product: Instruments, Assay, Kits, and Reagents
By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies
By Application: Cell Line Testing, Virus Testing, End-of-Production Cell Testing
By End User: Pharmaceutical and Biotechnology Companies, Cell Banks and Laboratories, Contract Research Organizations, Academic Research Institutes
By Geography: The regions covered in the mycoplasma testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Mycoplasma Testing Global Market Report 2022provides market size and growth forecasts for the global mycoplasma testing market, global mycoplasma testing market share, mycoplasma testing market segments and geographies, mycoplasma testing market competitive landscape including leading competitors’ revenues, profiles and market shares. The mycoplasma testing market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Mycoplasma Testing Industry Playersinclude Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott and Roche Diagnostics. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.